TG1050, a novel immunotherapeutic for the treatment of chronic hepatitis B, can control HBsAg and provoke HBsAg seroconversion in HBV-persistent mouse models

Autor: Lélu, K., Evlachev, A., Kratzer, R., Godon, O., Mancini-Bourgine, M., Dion, S., Schmitt, D., Dubois, C., Meritet, J.F., Schlesinger, Y., Marchand, J.B., Geist, M., Brandely, R., Findeli, A., Zhu, R., Menguy, T., Silvestre, N., Michel, M.L., Inchauspé, G., Martin, P.
Zdroj: In Journal of Clinical Virology August 2015 69:227-227
Databáze: ScienceDirect
Externí odkaz: